This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Hypertrophic cardiomyopathy (HCM) is commonly associated with atrialfibrillation (AF), but its impact on outcomes in real-world practice is uncertain. Patients with AF had a higher annual incidence of stroke/transient ischaemic attack (2.6 Methods Overall, 1739 adult patients with HCM (40.9% vs 1.7%, p=0.053).
Atrialfibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. This condition can lead to various complications, including stroke and heart failure, making it essential to understand its causes, symptoms, and AFib treatment options. What is AtrialFibrillation?
In particular, the study showed superiority in the percentage of patients that achieved freedom from atrialfibrillation (AF) with or without anti-arrhythmic drugs at 12 months after a tailored cardiac ablation guided by AI in combination with PVI when compared to PVI alone. tim.hodson Fri, 02/14/2025 - 09:57 Feb. adult population.
Background Atrialfibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both conditions. Whether the risks of outcomes differ according to temporal order of AF and AMI is unclear.
This review provides information about the current evidence-base for screening for atrialfibrillation (AF). Finally, novel methods to refine the population to whom AF screening should be offered, which may improve clinical and cost-effectiveness, are considered.
Twelve-month outcomes data from the pilot phase of the admIRE study, which assessed the safety and efficacy of the VARIPULSE Platform among U.S. 1 Among 20 patients who completed the 12-month follow-up visit, 100% achieved acute success from ablation procedures and 80% remained free from atrial arrhythmia recurrence at one year.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. Circulation.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrialfibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
IntroductionAtrial fibrillation (AF) is a prevalent cardiac arrhythmia and a significant contributor to cardioembolic stroke, a condition closely linked to cognitive decline. However, research reveals that AF itself is independently associated with an increased risk of cognitive impairment.
The collaboration, according to a written statement issued by the company, aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrialfibrillation procedures. Estimates of current and future incidence and prevalence of atrialfibrillation in the U.S.
Atrialfibrillation is the most common cardiac arrhythmia worldwide with around 59 million people concerned in 2019. This irregular heartbeat is associated with increased risks of heart failure, dementia and stroke. It constitutes a significant burden to healthcare systems, making its early detection and treatment a major goal.
BackgroundAn increased risk of recurrent stroke is noted in patients with atrialfibrillation despite direct oral anticoagulant (DOAC) use. A total of 84 patients experienced recurrent ischemic stroke after switching to different oral anticoagulants, with a total follow‐up time of 14 years. 0.41] for rivaroxaban).ConclusionsIn
BackgroundThe effectiveness of statin use in preventing adverse cardiovascular events in individuals with atrialfibrillation (AF) has remained uncertain. Journal of the American Heart Association, Volume 13, Issue 24 , December 17, 2024.
The primary efficacy and safety outcomes were stroke or systemic embolic events (stroke/SEE) and major bleeding, respectively; secondary outcomes were ischemic stroke/SEE, intracranial hemorrhage, death, and the net clinical outcome (stroke/SEE, major bleeding, or death). interquartile range, 25.2–32.2)
Background Efforts to maintain sinus rhythm in patients with persistent atrialfibrillation (PsAF) remain challenging, with suboptimal long-term outcomes. At 36 months, all patients were alive with no new stroke/transient ischaemic attack (TIA). All were longstanding persistent.
Background The impact of early rhythm control (ERC) combined with healthy lifestyle (HLS) on the risk of ischemic stroke in elderly patients with atrialfibrillation (AF) remains unaddressed. Objective To evaluate the impact of combined ERC and HLS on the risk of stroke in elderly patients with new-onset AF.
The ‘1–3–6–12 days rule’, based on expert consensus and referring to stroke severity, was used in clinical practice to initiate OAC after acute ischaemic stroke or transient ischaemic attack (TIA) since publication in 2013. Trial registration number NCT02306824.
Stroke recovery is a challenging process that extends for months after hospital discharge. To improve outcomes and be in compliance with new regulations, it's crucial to better identify and address these issues during the recovery period. After the stroke, I had new prescriptions, and this was the first obstacle for me.
Patients with atrialfibrillation, particularly older patients, are frequently at a high risk of bleeding. In patients with atrialfibrillation, abelacimab reduced rates of bleeding relative to rivaroxaban regardless of bleeding risk, with greater absolute safety benefit in those at higher bleeding risk.
BackgroundPatients with atrialfibrillation (AF) who suffered a previous stroke are at increased risk of recurrent thromboembolic events and other major outcomes. female) included, 2251 (10.6%) had a previous history of stroke, and 216 (1.0%) had 2 or more strokes. Among 21 223 patients (mean age: 70.210.3
Atrialfibrillation is the most common sustained arrhythmia. Females with atrialfibrillation have been known to have an increased risk of stroke. However, racial disparities in outcomes in atrialfibrillation patients have been less studied.
AF Often Asymptomatic: Even for atrialfibrillation (AF)the most commonly symptomatic arrhythmiaover half of all cases were asymptomatic. If left untreated, certain arrhythmias can damage the heart, brain, or other organs 4 and increase the risk of stroke or death. The American Journal of Cardiology. 2013;112(8):1263-1270.
million Americans have atrialfibrillation. Atrialfibrillation, a rapid, irregular heart beat that can lead to stroke or sudden death, is three times more common than previously thought, affecting nearly 5 percent of the population, or 10.5 tim.hodson Wed, 09/11/2024 - 15:40 Sept. million U.S. million U.S.
Background The Heart Failure Association Pretest assessment, echocardiography and natriuretic peptide, functional testing and final aetiology (HFA-PEFF) score has been developed for diagnosing heart failure with preserved ejection fraction (HFpEF), which is frequently associated with atrialfibrillation (AF).
Rate vs Rhythm Control in AtrialFibrillation Rate vs rhythm control as a management strategy in atrialfibrillation has been a long standing topic for debate. EAST-AFNET 4 trial had 2789 patients with early atrialfibrillation and cardiovascular conditions [8].
BackgroundThrombocytopenia is often associated with adverse outcomes in patients with atrialfibrillation. ResultsA total of 12 studies included 73,824 patients with atrialfibrillation (average age: 72.67, males: 42,275, 57.3%), among them, there were 7,673 patients combined with thrombocytopenia.
18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to treat people with atrialfibrillation (AFib) who are at an increased risk of stroke. A statistically significant lower number of fatal or disabling strokes with Amulet (22 vs. 39). 16-18, 2024).
Stroke, Volume 56, Issue Suppl_1 , Page ADP39-ADP39, February 1, 2025. Background:Patients with atrialfibrillation were excluded from clinical trials evaluating carotid artery stent(CAS) or carotid endarterectomy (CEA).We We divided patients based on presence or absence of atrialfibrillation. versus 18.8%
Introduction Atrialfibrillation (AF) is associated with a fivefold increased risk of stroke. Oral anticoagulation reduces the risk of stroke, but AF is elusive.
BackgroundThe impact of atrialfibrillation (AF) on the clinical outcomes in patients with acute ischemic stroke (AIS) who received endovascular thrombectomy remains unclear. Data were meta‐analyzed to compare the outcomes among patients with AIS with and without AF who received endovascular thrombectomy.
Recent trial results led to a renewed consideration of rhythm control therapy to improve outcomes in patients with atrialfibrillation (AF)1,2. The resulting shift towards rhythm control therapy for most patients with atrialfibrillation is reflected by new recommendations in the recent ESC3 and ACC/AHA/HRS4 AF guidelines.
BackgroundAs the population ages, atrialfibrillation (AF) prevalence increases, but data on optimal oral anticoagulation (OAC) in patients 80 years remain limited. Data were analyzed by age for outcomes and risk factors for predefined end points.ResultsPatients 80 years comprised 32.2% of AF cases. of AF cases. versus 70.5%,P=0.0070).
Background The value of empirical superior vena cava isolation (SVCI) following pulmonary vein isolation (PVI) to improve the efficacy of radiofrequency catheter ablation (RFCA) for paroxysmal atrialfibrillation (PAF) remains controversial.
Background Atrialfibrillation (AF) is the most common cardiac arrhythmia and is associated with a high risk of stroke. Finally, four indicators were included, namely, previous stroke/transient ischaemic attack (OR = 4.25, 95% CI = 1.57–12.23, 12.23, P = 0.006), left atrial volume index (LAVI) (OR = 1.04, 95% CI = 1.01–1.06,
Objective Implantable loop recorders (ILRs) are increasingly used for long-term rhythm monitoring after ischaemic and cryptogenic stroke, with the goal of detecting atrialfibrillation (AF) and subsequent initiation of oral anticoagulation to reduce risk of adverse clinical outcomes. Mean age was 69.9 (SD years and 53.5%
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation [abstract].
Stroke, Ahead of Print. Background:Novel oral anticoagulants (NOACs) are currently recommended for the secondary prevention of stroke in patients with acute ischemic stroke (AIS) accompanied by atrialfibrillation (AF). However, the impact of NOACs on clinical outcomes in real-world practice remains ambiguous.
Stroke, Volume 56, Issue Suppl_1 , Page ATP23-ATP23, February 1, 2025. Background:Stroke is the second leading cause of death worldwide, with atrialfibrillation being a significant risk factor that substantially increases the likelihood of stroke. The primary safety outcome was major bleeding. to 0.87, p = 0.005).
Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrialfibrillation (NVAF) treatment. Patients with NVAF deemed appropriate for LAAX to reduce the risk of stroke and systemic embolism, will participate in this research effort.
Atrialfibrillation (AF) is a common arrhythmia in patients with heart failure (HF). The coexistence of these conditions can further induce structural changes and result in worsened outcomes such as stroke, HF decompensation, poorly controlled AF, and mortality [1].
Background Evaluating outcomes of concurrent Cox-Maze procedures in elderly patients undergoing high-risk cardiac surgery. Mehods We retrospectively identified patients aged over 70 years with AtrialFibrillation (AF) from 2011 to 2017 who had two or more other cardiac procedures. They were subdivided into two groups: 1.
Stroke, Volume 55, Issue Suppl_1 , Page ATMP87-ATMP87, February 1, 2024. Background and purpose:Because the biochemical composition of thrombus changes after formation over time, thrombus maturation in the left atrium may affect clot compositions in ischemic stroke with atrialfibrillation (AF).
Background:While anticoagulation is crucial for atrialfibrillation (AF) patients to prevent ischemic events, those with thrombocytopenia have a potential increased risk of bleeding. The primary outcome was all-cause inpatient mortality. There was no significant difference in ischemic stroke risk (aOR 0.67, 95% CI 0.37-1.21,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
88 
Let's personalize your content